Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011018 | 1.00 | CA2 (0.33) | CA2TMEM97SIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL7078356 | 1.00 | CA2 (0.33) | CA2TMEM97SIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL1826271 | 0.82 | CA2 (0.35) | CA2TMEM97SIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL3020689 | 0.82 | CA2 (0.35) | CA2TMEM97SIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL883211 | 0.82 | CA2 (0.35) | CA2TMEM97SIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL1030223 | 0.80 | HCRTR2 (0.39) | CA2TMEM97SIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL2038232 | 0.80 | HCRTR2 (0.39) | CA2TMEM97SIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL1030224 | 0.80 | HCRTR2 (0.39) | CA2TMEM97SIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL8875465 | 0.80 | CA2 (0.34) | CA2TMEM97SIGMAR1HCRTR2HCRTR1 | |
| SCHEMBL9162631 | 0.78 | HCRTR2 (0.38) | CA2TMEM97SIGMAR1HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| EP-1888597-A2 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070281916-A1 | Substituted isoxazolines and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | disclosed |
| EP-1286998-B2 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| US-7176229-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| US-7141583-B2 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| WO-2006120563-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-11-16 | — | — | WO | disclosed |
| CN-1277829-C | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2006-10-04 | — | — | CN | disclosed |
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-6716871-B2 | OBESITY; INFLAMMATORY DISEASES, DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, CENTRAL NERVOUS SYSTEM DISORDERS; 3-HYDROXYALKYL-4-DIALKOXYPHENYL-SUBSTITUTED PYRROLIDINES | ICOS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| CN-1437603-A | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | CN | disclosed |
| CN-1434813-A | Pyrrolidine derivatives cyclic AMP-specific phosphodiesterase inhibitors | ICOS CONP (US) | 2003-08-06 | — | — | CN | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
| US-6423710-B1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | CA2 2097/4885TMEM97 3146/4885SIGMAR1 1408/4885 |
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE7A | CA2 2575/4885TMEM97 4616/4885SIGMAR1 4158/4885 |
| US-20070281916-A1 | Substituted isoxazolines and their use as antibacterial agents | CYP2S1, CYP3A7, CYP3A5 | CA2 2154/4885TMEM97 1497/4885SIGMAR1 533/4885 |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | STS, SULT1E1, OXA1L | CA2 2540/4885TMEM97 2517/4885SIGMAR1 610/4885 |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | CA2 3651/4885TMEM97 3866/4885SIGMAR1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.